MX391097B - FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. - Google Patents
FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.Info
- Publication number
- MX391097B MX391097B MX2020005442A MX2020005442A MX391097B MX 391097 B MX391097 B MX 391097B MX 2020005442 A MX2020005442 A MX 2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A MX 391097 B MX391097 B MX 391097B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulation
- hydroxyandrostan
- oxime
- ethinyl
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590757P | 2017-11-27 | 2017-11-27 | |
| PCT/EP2018/082727 WO2019102040A1 (en) | 2017-11-27 | 2018-11-27 | PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020005442A MX2020005442A (es) | 2022-03-30 |
| MX391097B true MX391097B (es) | 2025-03-21 |
Family
ID=64556898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005442A MX391097B (es) | 2017-11-27 | 2018-11-27 | FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10603326B2 (https=) |
| EP (1) | EP3716954A1 (https=) |
| JP (1) | JP7314459B2 (https=) |
| KR (1) | KR102771577B1 (https=) |
| CN (1) | CN111432805B (https=) |
| AU (1) | AU2018374029B2 (https=) |
| BR (1) | BR112020010519A2 (https=) |
| CA (1) | CA3083555A1 (https=) |
| IL (1) | IL274893B2 (https=) |
| MX (1) | MX391097B (https=) |
| UA (1) | UA128186C2 (https=) |
| WO (1) | WO2019102040A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3716954A1 (en) | 2017-11-27 | 2020-10-07 | Umecrine Cognition AB | Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime |
| EP4079307A1 (en) | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| EP4389129A1 (en) | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
| WO2025252725A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
| WO2025252724A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE511313C2 (sv) | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
| GB9907715D0 (en) | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
| US20040191207A1 (en) | 2003-03-31 | 2004-09-30 | Lipari John M. | Alpha-hydroxy acid ester drug delivery compositions and methods of use |
| US20100209496A1 (en) | 2006-09-06 | 2010-08-19 | Eleni Dokou | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| DK2792681T3 (en) | 2006-11-21 | 2017-01-23 | Umecrine Ab | Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders. |
| RU2012133627A (ru) | 2010-01-14 | 2014-04-20 | Умекрине Муд Аб | Фармацевтическая композиция, содержащая 3-бета-гидрокси-5-альфа-прегнан-20-он, с улучшенными свойствами хранения и растворимости |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US9801819B2 (en) | 2012-06-28 | 2017-10-31 | Johnson & Johnson Consumer Inc. | Racecadotril compositions |
| HK1223300A1 (zh) * | 2013-06-03 | 2017-07-28 | Tolmar, Inc. | 皮质类固醇组合物 |
| RU2684616C2 (ru) * | 2014-01-29 | 2019-04-10 | Умекрин Когнишн Аб | Стероидное соединение для применения в лечении печеночной энцефалопатии |
| WO2015193224A1 (en) | 2014-06-17 | 2015-12-23 | Merck Sharp & Dohme B.V. | Stable formulations of testosterone undecanoate |
| US9498485B2 (en) * | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| KR101679992B1 (ko) | 2015-12-31 | 2016-11-28 | 주식회사 유유제약 | 프로필렌글리콜 모노라우레이트를 포함하는 두타스테리드의 약학적 조성물 및 이의 제조 방법 |
| KR101716878B1 (ko) | 2016-05-12 | 2017-03-15 | 주식회사 유유제약 | 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법 |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| EP3716954A1 (en) | 2017-11-27 | 2020-10-07 | Umecrine Cognition AB | Pharmaceutical formulation of 3 -ethynyl-3 -hydroxyandrostan-17-one oxime |
-
2018
- 2018-11-27 EP EP18811225.4A patent/EP3716954A1/en active Pending
- 2018-11-27 KR KR1020207018543A patent/KR102771577B1/ko active Active
- 2018-11-27 UA UAA202003834A patent/UA128186C2/uk unknown
- 2018-11-27 CN CN201880076423.8A patent/CN111432805B/zh active Active
- 2018-11-27 BR BR112020010519-8A patent/BR112020010519A2/pt unknown
- 2018-11-27 MX MX2020005442A patent/MX391097B/es unknown
- 2018-11-27 WO PCT/EP2018/082727 patent/WO2019102040A1/en not_active Ceased
- 2018-11-27 AU AU2018374029A patent/AU2018374029B2/en active Active
- 2018-11-27 CA CA3083555A patent/CA3083555A1/en active Pending
- 2018-11-27 JP JP2020545883A patent/JP7314459B2/ja active Active
- 2018-11-27 IL IL274893A patent/IL274893B2/en unknown
-
2019
- 2019-06-24 US US16/450,620 patent/US10603326B2/en active Active
-
2020
- 2020-02-21 US US16/797,426 patent/US11123351B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL274893B1 (en) | 2024-04-01 |
| KR20200093008A (ko) | 2020-08-04 |
| EP3716954A1 (en) | 2020-10-07 |
| US20190358244A1 (en) | 2019-11-28 |
| CN111432805B (zh) | 2023-02-17 |
| MX2020005442A (es) | 2022-03-30 |
| US11123351B2 (en) | 2021-09-21 |
| RU2020121142A3 (https=) | 2022-03-28 |
| AU2018374029B2 (en) | 2024-01-11 |
| IL274893B2 (en) | 2024-08-01 |
| US20200297737A1 (en) | 2020-09-24 |
| IL274893A (en) | 2020-07-30 |
| CN111432805A (zh) | 2020-07-17 |
| UA128186C2 (uk) | 2024-05-01 |
| NZ764901A (en) | 2025-05-02 |
| US10603326B2 (en) | 2020-03-31 |
| CA3083555A1 (en) | 2019-05-31 |
| KR102771577B1 (ko) | 2025-02-20 |
| WO2019102040A1 (en) | 2019-05-31 |
| AU2018374029A1 (en) | 2020-06-18 |
| BR112020010519A2 (pt) | 2020-10-20 |
| JP7314459B2 (ja) | 2023-07-26 |
| RU2020121142A (ru) | 2021-12-29 |
| JP2021504468A (ja) | 2021-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391097B (es) | FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. | |
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CO2020005887A2 (es) | Compuestos policíclicos como inhibidores alostéricos de shp2 | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| UY36077A (es) | Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen | |
| CL2018001868A1 (es) | Análogos del egf(a) con sustituyentes de ácidos grasos. | |
| MX2023006541A (es) | Formulaciones de dosis fija. | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| MX2017006113A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
| AR125457A2 (es) | Compuestos inhibidores dobles de magl y faah y composición farmacéutica | |
| MX2016004530A (es) | Rapamicina para el tratamiento de linfangioleiomiomatosis. | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| MX2018001756A (es) | Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos. | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |